OS Therapies Inc. Makes Strides in Rare Cancer Therapy with Breakthrough Potential in Osteosarcoma

Strategic Insights -

OS Therapies Inc. (NYSE-A: OSTX) is making significant progress in the fight against rare cancers, particularly osteosarcoma, with its lead candidate, OST-HER2, demonstrating statistically significant survival benefits in patients with recurrent fully resected lung metastatic osteosarcoma. The company's immunotherapy, designed to activate the immune system against HER2-expressing cancer cells, has shown a favorable safety profile, with no patients experiencing grade four or grade five treatment-associated adverse events. Regulatory agencies are accelerating these advances with tools like Fast Track and Accelerated Approval, creating a favorable environment for OSTX's progress.

Key Takeaways:

  • OST-HER2, OS Therapies' lead candidate, has shown statistically significant survival benefits in patients with recurrent fully resected lung metastatic osteosarcoma.
  • The company's immunotherapy has a favorable safety profile, with no patients experiencing grade four or grade five treatment-associated adverse events.
  • Regulatory agencies are accelerating advances in rare cancer therapies with tools like Fast Track and Accelerated Approval.
  • OSTX's regulatory engagement is progressing in both the United States and Europe, potentially paving the way for a Priority Review Voucher.
  • The company is also advancing its tunable antibody drug conjugate platform, built around proprietary Si-Linker and Conditionally Active Payload technologies, to improve therapeutic precision.
  • OS Therapies has formed two new subsidiaries, OS Animal Health and OS Drug Conjugates, to explore commercial applications in comparative oncology and targeted therapeutics.
  • The company has secured multiple regulatory designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for OST-HER2.
  • A Priority Review Voucher, which could bring in significant non-dilutive funding, is a potential reward for agreement to initiate a rolling Biologics License Application submission.

Statistics:

  • The global oncology drug market is valued at over $200 billion and is expected to more than double to $532 billion by 2031.
  • 35 percent of patients treated with OST-HER2 achieved one-year event-free survival compared to 20 percent in a peer-reviewed historical control group.
  • The p-value of 0.0194 suggests the result is statistically significant.
  • No patients experienced grade four or grade five treatment-associated adverse events.
  • The U.S. Food and Drug Administration has scheduled an End of Phase 2 meeting with OS Therapies for August 27, 2025.
  • If OST-HER2 is approved before September 30, 2026, OS Therapies will be eligible to receive a Priority Review Voucher.

Sources:

  • M2 PRESSWIRE, July 14, 2025, "OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy (C)1994-2025 M2 COMMUNICATIONS RDATE:14072025"
  • RazorPitch Inc. website, accessed on [date]